News & Partnering

Press releases

December 2, 2025

Imvax Announces Positive Top-line Data from Phase 2b Clinical Trial of IGV-001 in Newly Diagnosed GBM

January 29, 2025

Imvax Announces Completion of $29 Million Financing and Confirms Timing for Topline Results of Phase 2b Trial of IGV-001 in Newly Diagnosed Glioblastoma

November 11, 2024

Imvax to Present Safety Data on Lead Program, IGV-001, at 2024 SNO Annual Meeting

May 21, 2024

Imvax Announces Completion of Enrollment in Phase 2b Clinical Trial of IGV-001 and Successful Financing

In the News

December 2, 2025 | Endpoints News

Imvax shares Phase 2b data for glioblastoma treatment, plans to meet with FDA

December 2, 2025 | Targeted Oncology

IGV-001 Offers Hope for Prolonged OS in Newly Diagnosed Glioblastoma

Upcoming Events

None at this time, stay tuned!